Navigation Links
MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
Date:9/10/2007

VANCOUVER and SAN DIEGO, Sept. 10 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases will present results of viral resistance studies with its anti-HCV agent celgosivir at the 14th International Symposium on Hepatitis C Virus and Related Viruses (http://www.hcv2007.com) being held September 9th to 13th 2007 in Glasgow, Scotland.

The presentation entitled: "Celgosivir (MX-3253) Resistance Profile Using Bovine Viral Diarrhea Virus" will be made today from 5:30pm to 8:00pm, Glasgow time (9:30am - noon Pacific Time) by Dominique Dugourd, Ph.D., Microbiology Group Leader at MIGENIX. A copy of the presentation and the related Abstract (abstract P-223) will be available at http://www.migenix.com at the start of the presentation. The conference covers a broad spectrum of topics from molecular virology to new antiviral therapies and attracts major scientists and thought leaders in the field.

Jacob Clement, Ph.D., CSO at MIGENIX and coauthor of the paper, believes that the results of these laboratory studies with the accepted HCV surrogate virus BVDV, indicate that the emergence of resistance in a clinical setting is unlikely to occur. "We were unable to induce viral resistance to celgosivir even after repeated exposure to high levels of the agent in a system which rapidly develops relatively high levels of resistance to other direct acting antivirals."

About Celgosivir (MX-3253)

Celgosivir is an oral alpha-glucosidase I inhibitor and is currently the only anti-HCV drug in clinical development that acts on host-directed glycosylation. In preclinical studies, celgosivir has shown excellent in vitro synergy with various interferons in the clinic or in development including Pegasys, PEG-Intron, Infergen, Alferon and IFN-omega (with or without ribavirin) and other drugs in develo
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... The participants committed to not only creating unique ... time adjusting, tweaking and testing virtual models and 3D ... judging. , “I enjoyed being involved as a judge,” ... entries showed a commendable range exploring the technical capabilities ... medium and the creativity of the contestants.” , Array ...
(Date:10/1/2014)... 30, 2014 New applications of structures ... have evolved in nature over millennia are featured in ... for applications in biophotonics in the October issue ... journal is published by SPIE, the international society for ... of the peer-reviewed articles are accessible via open access. ...
(Date:10/1/2014)... TeselaGen Biotechnology has received ... expand their bioCAD/CAM software suite, which uses synthetic ... Small Business Innovation Research Phase II grant will be ... license from the Lawrence Berkeley National Laboratory. j5 was ... LBNL laboratory that develops alternative fuel technologies for the ...
(Date:10/1/2014)... 2014 Industry leaders from ... engage around the theme, ,Commercial Opportunities in the Era ... Elsevier , a world-leading provider of ... host a gathering of some of the industry,s most ... healthcare today and in the future. The ...
Breaking Biology Technology:Array Architects Challenges Staff to Create with 3D Printer 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 3TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3
... NicOx S.A.,(NYSE Euronext Paris: COX) today announced ... the commercial manufacture and supply of naproxcinod ... is NicOx, lead,investigational product and the first ... of,anti-inflammatory agents, which recently achieved positive results ...
... Sinovac Biotech Ltd. (NYSE Alternext,US: SVA), a leading provider of ... Fengtai District in the City of Beijing suspended,the use of ... of the death of a minor in the Fengtai District ... vaccine two days prior. , ...
... market research firm SharpBrains, will lead a webinar discussing the Top ... providers. , ... San Francisco, CA (PRWEB) December 2, ... World Economic Forum,s Council on the Challenges of Gerontology, will lead ...
Cached Biology Technology:NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 2NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 3NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 4Sinovac Releases Statement on Healive Vaccine Suspension 2Top 10 Cognitive Fitness Events of 2008 to be Unveiled at SharpBrains' Webinar 2Top 10 Cognitive Fitness Events of 2008 to be Unveiled at SharpBrains' Webinar 3
(Date:10/1/2014)... microbes that thrive in the deserts, rainforests, prairies and ... beneath New York City,s Central Park, according to a ... the University of Colorado Boulder. , The research ... Park,s 843 acres and discovered a stunning diversity of ... before. , Only 8.5 percent to 16.2 percent ...
(Date:9/30/2014)... by the Ocean Health Index rates the Earth,s ... health. In addition, for the first time, the ... regions beyond national jurisdiction (high-seas areas) all ... biodiversity and providing sustainable food sources. , In ... partnership led by scientists from UC Santa Barbara,s ...
(Date:9/30/2014)... scientists and engineers, led by Clemson University associate ... million grant from the U.S. Department of Energy,s ... a direct positive impact on South Carolina in ... radioactive contaminants. , "Understanding the scientific and engineering ... aspects of nuclear technologies is imperative if South ...
Breaking Biology News(10 mins):Microbes in Central Park soil: If they can make it there, they can make it anywhere 2Microbes in Central Park soil: If they can make it there, they can make it anywhere 3Rating the planet's oceans 2Rating the planet's oceans 3Researchers get $5.25 million to advance nuclear technologies in South Carolina 2
... (March 5, 2013) Researchers have discovered that deleting a ... on a high fat diet, a finding they believe may ... induces obesity these mice don,t get fat," said Prof. James ... research for Obstetrics and Gynecology at the University of Colorado ...
... Center scientists report the first successful blocking of tumor development in ... my knowledge, this is the first time that a mouse model ... which the formation of the tumor from beginning to end can ... of the tumor," said Dr. Luis Parada , chair of ...
... 2013) Researchers at the University of Minnesota,s ... cellular reprogramming to generate stem cells capable of ... Muscular Dystrophy (DMD). The research, which ... pluripotent stem cell technology and genetic correction to ...
Cached Biology News:Researchers discover gene that causes obesity in mice 2UT Southwestern scientists make mouse model of human cancer, demonstrate cure 2UT Southwestern scientists make mouse model of human cancer, demonstrate cure 3U of M researchers utilize genetically corrected stem cells to spark muscle regeneration 2U of M researchers utilize genetically corrected stem cells to spark muscle regeneration 3
Mouse monoclonal [7B9] to beta II Tubulin ( Abpromise for all tested applications). Antigen: Synthetic peptide, CEEEEGEDEA found at the c-terminus of beta II tubulin. Entrez GeneID: 10383 ...
...
... used in conjuction with Annexin V-FITC to ... stages of apoptosis (Annexin V positive, PI ... stages of apoptosis or already dead (Annexin ... in the orange range of the spectrum ...
... were cultured in RPMI 1640 with 2 mM ... growth. In order to keep the antigens ... acetone-methanol. The cells are arrayed on a ... wells surface specifically treated to enhance cellular attachment ...
Biology Products: